Chronic lymphocytic leukaemia - the role of the microenvironment pathogenesis and therapy

British Journal of Haematology

Volumn 162, Issue 1, 2013, Pages 15-24

  Ramsay, Alan D ^a   Rodriguez Justo, Manuel ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

BCR; CLL; Microenvironment; Signalling; Therapy

Indexed keywords

ALEMTUZUMAB; B LYMPHOCYTE RECEPTOR; FLUDARABINE; IMMUNOMODULATING AGENT; LENALIDOMIDE; NOTCH RECEPTOR; RITUXIMAB; THALIDOMIDE;

APOPTOSIS; CELL INTERACTION; CELL MIGRATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; ERYTHEMA; GENE EXPRESSION; HUMAN; LYMPHADENOPATHY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SPLENOMEGALY; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MOVEMENT; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84879101109     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12344     Document Type: Review

References (105)

1. Antony, P., Petro, J.B., Carlesso, G., Shinners, N.P., Lowe, J. & Khan, W.N. (2004) B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacylglycerol. Biochemical Society Transactions, 32, 113-115.
2. Bairey, O., Zimra, Y., Rabizadeh, E. & Shaklai, M. (2004) Expression of adhesion molecules on leukemic B cells from chronic lymphocytic leukemia patients with predominantly splenic manifestations. Israeli Medical Association Journal, 6, 147-151.
3. Baud, V. & Karin, M. (2009) Is NF-kB a good target for cancer therapy? Hopes and pitfalls. Nature Reviews Drug Discovery, 8, 33-40.
4. Bernhagen, J., Krohn, R., Lue, H., Gregory, J.L., Zernecke, A., Koenen, R.R., Dewor, M., Georgiev, I., Schober, A., Leng, L., Kooistra, T., Fingerle-Rowson, G., Ghezzi, P., Kleemann, R., McColl, S.R., Bucala, R., Hickey, M.J. & Weber, C. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nature Medicine, 13, 587-596.
5. Borghese, F. & Clanchy, F.I. (2011) CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opinion on Therapeutic Targets, 15, 237-251.
6. Borland, G. & Cushley, W. (2004) Positioning the immune system: unexpected roles for alpha6-integrins. Immunology, 111, 3810383.
7. Bulian, P., Shanafelt, T.D., Pepper, C., Fegan, C., Del Poeta, G., Gaidano, G., Rossi, D., Baldini, L., Cro, L., Nuckel, H., Burger, J.A. & Gattei, V. (2012). Prognostic relevance of CD49d expression on B leukemic cells in chronic lymphocytic leukemia. Meta-analysis of published and unpublished individual data from 3146 patients. Blood (ASH Annual Meeting-Abstracts), 120, 3871.
8. Burger, J.A. (2010) Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. Seminars in Cancer Biology, 20, 424-430.
9. Burger, J.A. (2012) Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Current Opinions in Oncology, 24, 643-649.
10. Burger, J.A. & Kipps, T.J. (2002) Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leukemia & Lymphoma, 43, 461-466.
11. Burger, J.A., Tsukada, N., Burger, M., Zvaifler, N.J., Dell'Aquila, M. & Kipps, T.J. (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood, 96, 2655-2663.
12. Burger, M., Hartmann, T., Krome, M., Rawluk, J., Tamamura, H., Fujii, N., Kipps, T.J. & Burger, J.A. (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood, 106, 1824-1830.
13. Bürkle, A., Niedermeier, M., Schmitt-Gräff, A., Wierda, W.G., Keating, M.J. & Burger, J.A. (2007) Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood, 110, 3316-3325.
14. Calandra, G., Bridger, G. & Fricker, S. (2010) CXCR4 in clinical hematology. Current Topics in Microbiology and Immunolgy, 341, 173-191.
15. Carballido, E., Veliz, M., Komrokji, R. & Pinilla-Ibarz, J. (2012) Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control, 19, 54-67.
16. Chanan-Khan, A. & Porter, C.W. (2006) Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncology, 7, 480-488.
17. Chen, C.I. (2013) Lenalidomide alone and in combination for Chronic Lymphocytic Leukemia. Current Hematologic Malignant Reports, 8, 7-13.
18. Chen, L., Widhopf, G., Huynh, L., Rassenti, L., Rai, K.R., Weiss, A. & Kipps, T.J. (2002) Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood, 100, 4609-4614.
19. Chen, L.S., Redkar, S., Bearss, D., Wierda, W.G. & Gandhi, V. (2009) Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 114, 4150-4157.
20. Chen, L.S., Balakrishnan, K. & Gandhi, V. (2010) Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochemical Pharmacology, 80, 1936-1945.
21. Chiorazzi, N. & Efremov, D.G. (2013) Chronic lymphocytic leukemia: a tale of one or two signals? Cell Research, 23, 182-185.
22. Chiorazzi, N. & Ferrarini, M. (2003) B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annual Review of Immunology, 21, 841-894.
23. Codony, C., Crespo, M., Abrisqueta, P., Montserrat, E. & Bosch, F. (2009) Gene expression profiling in chronic lymphocytic leukaemia. Best Practice & Research. Clinical Haematology, 22, 211-222.
24. Cortelezzi, A., Sciumè, M. & Reda, G. (2012) Lenalidomide in the treatment of chronic lymphocytic leukemia. Advances in Hematology, 2012, 393864. doi:10.1155/2012/393864.Epub 2012 May 8
25. Costantini, J.L., Cheung, S.M., Hou, S., Li, H., Kung, S.K., Johnston, J.B., Wilkins, J.A., Gibson, S.B. & Marshall, A.J. (2009) TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia. Blood, 114, 4703-4712.
26. Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, 1840-1847.
27. Davids, M.S. & Burger, J.A. (2012) Cell trafficking in chronic lymphocytic leukemia. Open Journal of Hematology, 3, Suppl 1.
28. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Muller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88-92.
29. Deans, R.J. & Moseley, A.B. (2000) Mesenchymal stem cells: biology and potential clinical uses. Experimental Hematology, 28, 875-884.
30. Dietrich, S., Krämer, O.H., Hahn, E., Schäfer, C., Giese, T., Hess, M., Tretter, T., Rieger, M., Hüllein, J., Zenz, T., Ho, A.D., Dreger, P. & Luft, T. (2012) Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells. Clinical Cancer Research, 18, 417-431.
31. Duda, D.G., Kozin, S.V., Kirkpatrick, N.D., Xu, L., Fukumura, D. & Jain, R.K. (2011) CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clinical Cancer Research, 17, 2074-2080.
32. Dühren-von Minden, M., Übelhart, R., Schneider, D., Wossning, T., Bach, M.P., Buchner, M., Hofmann, D., Surova, E., Follo, M., Köhler, F., Wardemann, H., Zirlik, K., Veelken, H. & Jumaa, H. (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature, 489, 309-312.
33. Dürig, J., Schmücker, U. & Dührsen, U. (2001) Differential expression of chemokine receptors in B cell malignancies. Leukemia, 15, 752-756.
34. Dylke, J., Lopes, J., Dang-Lawson, M., Machtaler, S. & Matsuuchi, L. (2007) Role of the extracellular and transmembrane domain of Ig-alpha/beta in assembly of the B cell antigen receptor (BCR). Immunology Letters, 112, 47-57.
35. Eichhorst, B.F., Busch, R., Stilgenbauer, S., Stauch, M., Bergmann, M.A., Ritgen, M., Kranzhöfer, N., Rohrberg, R., Söling, U., Burkhard, O., Westermann, A., Goede, V., Schweighofer, C.D., Fischer, K., Fink, A.M., Wendtner, C.M., Brittinger, G., Döhner, H., Emmerich, B. & Hallek, M., GCLLSG (German CLL Study Group). (2009) First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood, 114, 3382-3391.
36. Friedberg, J.W., Sharman, J., Sweetenham, J., Johnston, P.B., Vose, J.M., Lacasce, A., Schaefer-Cutillo, J., De Vos, S., Sinha, R., Leonard, J.P., Cripe, L.D., Gregory, S.A., Sterba, M.P., Lowe, A.M., Levy, R. & Shipp, M.A. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 115, 2578-2585.
37. Gore, Y., Starlets, D., Maharshak, N., Becker-Herman, S., Kaneyuki, U., Leng, L., Bucala, R. & Shachar, I. (2008) Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. Journal of Biological Chemistry, 283, 2784-2792.
38. Görgün, G., Holderried, T.A., Zahrieh, D., Neuberg, D. & Gribben, J.G. (2005) Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. Journal of Clinical Investigation, 115, 1797-1805.
39. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., Von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H. & Stilgenbauer, S., International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
40. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, 1848-1854.
41. Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K.L., Ellmeier, W., Valent, P. & Superti-Furga, G. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proceedings of the National Academy of Science of the USA, 104, 13283-13288.
42. Hayden, R.E., Pratt, G., Roberts, C., Drayson, M.T. & Bunce, C.M. (2012) Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leukemia & Lymphoma, 53, 537-549.
43. Herishanu, Y., Perez-Galan, P., Liu, D., Biancotto, A., Pittaluga, S., Vire, B., Gibellini, F., Njuguna, N., Lee, E., Stennett, L., Raghavachari, N., Liu, P., McCoy, J.P., Raffeld, M., Stetler-Stevenson, M., Yuan, C., Sherry, R., Arthur, D.C., Maric, I., White, T., Marti, G.E., Munson, P., Wilson, W.H. & Wiestner, A. (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood, 117, 563-574.
44. Herman, S.E. & Johnson, A.J. (2012) Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clinical Cancer Research, 18, 4013-4018.
45. Hertlein, E., Triantafillou, G., Sass, E.J., Hessler, J.D., Zhang, X., Jarjoura, D., Lucas, D.M., Muthusamy, N., Goldenberg, D.M., Lee, R.J. & Byrd, J.C. (2010) Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood, 116, 2554-2558.
46. Hoellenriegel, J., Coffey, G.P., Sinha, U., Pandey, A., Sivina, M., Ferrajoli, A., Ravandi, F., Wierda, W.G., O'Brien, S., Keating, M.J. & Burger, J.A. (2012) Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia, 26, 1576-1583.
47. Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Altekruse, S.F., Kosary, C.L., Ruhl, J., Tatalovich, Z., Cho, H., Mariotto, A., Eisner, M.P., Lewis, D.R., Chen, H.S., Feuer, E.J. & Cronin, K.A. (eds). (2011) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09. Based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
48. Haematological Malignancy Research Network (HRMN) UK. Statistics - incidence information, chronic lymphocytic leukaemia 2004-2011. http://www.hmrn.org/Statistics/Cancer_Info.aspx?id=9.
49. Huber, S., Oelsner, M., Decker, T., zum Büschenfelde, C.M., Wagner, M., Lutzny, G., Kuhnt, T., Schmidt, B., Oostendorp, R.A., Peschel, C. & Ringshausen, I. (2011) Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia, 25, 838-847.
50. Kuckertz, M., Patz, M., Veldurthy, A., Gehrke, I., Claasen, J., Frenzel, L.P., Wendtner, C.M., Hallek, M. & Krause, G. (2012) Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells. Onkologie, 35, 420-426.
51. Kurtova, A.V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M.P., Sivina, M., Wierda, W.G., Estrov, Z., Keating, M.J., Shehata, M., Jäger, U., Gandhi, V., Kay, N.E., Plunkett, W. & Burger, J.A. (2009) Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood, 114, 4441-4450.
52. Lagneaux, L., Delforge, A., Bron, D., De Bruyn, C. & Stryckmans, P. (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood, 91, 2387-2396.
53. Lane, P., Traunecker, A., Hubele, S., Inui, S., Lanzavecchia, A. & Gray, D. (1992) Activated human T cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. European Journal of Immunology, 22, 2573-2578.
54. Liffraud, C., Quillet-Mary, A., Fournié, J.J., Laurent, G. & Ysebaert, L. (2012) Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells. Leukemia & Lymphoma, 53, 966-972.
55. Liu, Y.J., Joshua, D.E., Williams, G.T., Smith, C.A., Gordon, J. & MacLennan, I.C. (1989) Mechanism of antigen-driven selection in germinal centres. Nature, 342, 929-931.
56. Mao, Y., Triantafillou, G., Hertlein, E., Towns, W., Stefanovski, M., Mo, X., Jarjoura, D., Phelps, M., Marcucci, G., Lee, L.J., Goldenberg, D.M., Lee, R.J., Byrd, J.C. & Muthusamy, N. (2013) Milatuzumab-Conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical Cancer Research, 19, 347-356.
57. Masood, A., Sher, T., Paulus, A., Miller, K.C., Chitta, K.S. & Chanan-Khan, A. (2011) Targeted treatment for chronic lymphocytic leukemia. OncoTargets and Therapy, 4, 169-183.
58. McCaig, A.M., Cosimo, E., Leach, M.T. & Michie, A.M. (2011) Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. British Journal of Haematology, 153, 199-211.
59. Messmer, B.T., Albesiano, E., Efremov, D.G., Ghiotto, F., Allen, S.L., Kolitz, J., Foa, R., Damle, R.N., Fais, F., Messmer, D., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (2004) Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. Journal of Experimental Medicine, 200, 519-525.
60. Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D. & Linet, M.S. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood, 107, 256-276.
61. Nadkarni, J.J., Perambakam, S.M., Rathore, V.B., Amin, K.M., Parikh, P.M., Naresh, K.N. & Advani, S.H. (1998) Expression of adhesion molecules in B-cell chronic lymphocytic leukaemia: an analysis in lymphoid compartments-peripheral blood, bone marrow and lymph node. Cancer Biotherapy & Radiopharmaceuticals, 13, 269-274.
62. de Nigris, F., Schiano, C., Infante, T. & Napoli, C. (2012) CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Patents on Anticancer Drug Discovery, 7, 251-264.
63. Niiro, H. & Clark, E.A. (2002) Regulation of B-cell fate by antigen-receptor signals. Nature Reviews Immunology, 2, 945-956.
64. Nwabo Kamdje, A.H., Mosna, F., Bifari, F., Lisi, V., Bassi, G., Malpeli, G., Ricciardi, M., Perbellini, O., Scupoli, M.T., Pizzolo, G. & Krampera, M. (2011) Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood, 118, 380-389.
65. O'Hayre, M., Salanga, C.L., Kipps, T.J., Messmer, D., Dorrestein, P.C. & Handel, T.M. (2010) Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS ONE, 5, e11716.
66. Palomero, T., Lim, W.K., Odom, D.T., Sulis, M.L., Real, P.J., Margolin, A., Barnes, K.C., O'Neil, J., Neuberg, D., Weng, A.P., Aster, J.C., Sigaux, F., Soulier, J., Look, A.T., Young, R.A., Califano, A. & Ferrando, A.A. (2006) NOTCH1 directly regulates c-MYC and activates a feedforward-loop transcriptional network promoting leukemic cell growth. Proceedings of the National Academy of Sciences of the USA, 103, 18261-18266.
67. Palomero, T., Dominguez, M. & Ferrando, A.A. (2008) The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle, 7, 965-970.
68. Pighi, C., Gu, T.L., Dalai, I., Barbi, S., Parolini, C., Bertolaso, A., Pedron, S., Parisi, A., Ren, J., Cecconi, D., Chilosi, M., Menestrina, F. & Zamò, A. (2011) Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cellular Oncology (Dordrecht), 34, 141-153.
69. Ponader, S., Chen, S.S., Buggy, J.J., Balakrishnan, K., Gandhi, V., Wierda, W.G., Keating, M.J., O'Brien, S., Chiorazzi, N. & Burger, J.A. (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 119, 1182-1189.
70. Puente, X.S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G.R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., Bassaganyas, L., Baumann, T., Juan, M., López-Guerra, M., Colomer, D., Tubío, J.M., López, C., Navarro, A., Tornador, C., Aymerich, M., Rozman, M., Hernández, J.M., Puente, D.A., Freije, J.M., Velasco, G., Gutiérrez-Fernández, A., Costa, D., Carrió, A., Guijarro, S., Enjuanes, A., Hernández, L., Yagüe, J., Nicolás, P., Romeo-Casabona, C.M., Himmelbauer, H., Castillo, E., Dohm, J.C., de Sanjosé, S., Piris, M.A., de Alava, E., San Miguel, J., Royo, R., Gelpí, J.L., Torrents, D., Orozco, M., Pisano, D.G., Valencia, A., Guigó, R., Bayés, M., Heath, S., Gut, M., Klatt, P., Marshall, J., Raine, K., Stebbings, L.A., Futreal, P.A., Stratton, M.R., Campbell, P.J., Gut, I., López-Guillermo, A., Estivill, X., Montserrat, E., López-Otín, C. & Campo, E. (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 475, 101-105.
71. Qian, H., Tryggvason, K., Jacobsen, S.E. & Ekblom, M. (2006) Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins. Blood, 107, 3503-3510.
72. Rawstron, A.C. (2011) Occult B-cell lymphoproliferative disorders. Histopathology, 58, 81-89.
73. Riches, J.C., Ramsay, A.G. & Gribben, J.G. (2011) Chronic lymphocytic leukemia: an update on biology and treatment. Current Oncology Reports, 13, 379-385.
74. Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., Larratt, L., Geisler, C.H., Montillo, M., Zyuzgin, I., Ganly, P.S., Dartigeas, C., Rosta, A., Maurer, J., Mendila, M., Saville, M.W., Valente, N., Wenger, M.K. & Moiseev, S.I. (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1756-1765.
75. Romano, M.F., Lamberti, A., Tassone, P., Alfinito, F., Costantini, S., Chiurazzi, F., Defrance, T., Bonelli, P., Tuccillo, F., Turco, M.C. & Venuta, S. (1998) Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood, 92, 990-995.
76. de Rooij, M.F., Kuil, A., Geest, C.R., Eldering, E., Chang, B.Y., Buggy, J.J., Pals, S.T. & Spaargaren, M. (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood, 119, 2590-2594.
77. Rosati, E., Sabatini, R., Rampino, G., Tabilio, A., Di Ianni, M., Fettucciari, K., Bartoli, A., Coaccioli, S., Screpanti, I. & Marconi, P. (2009) Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood, 113, 856-865.
78. Saijo, K., Mecklenbräuker, I., Santana, A., Leitger, M., Schmedt, C. & Tarakhovsky, A. (2002) Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. Journal of Experimental Medicine, 195, 1647-1652.
79. Sanchez-Aguilera, A., Rattmann, I., Drew, D.Z., Müller, L.U., Summey, V., Lucas, D.M., Byrd, J.C., Croce, C.M., Gu, Y., Cancelas, J.A., Johnston, P., Moritz, T. & Williams, D.A. (2010) Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia. Leukemia, 24, 97-104.
80. Sarmento-Ribeiro, A.B., Proença, M.T., Sousa, I., Pereira, A., Guedes, F., Teixeira, A. & Oliveira, C.R. (2012) A possible role for oxidation stress in lymphoid leukaemias and therapeutic failure. Leukemia Research, 36, 1041-1048.
81. Scielzo, C., Bertilaccio, M.T., Simonetti, G., Dagklis, A., ten Hacken, E., Fazi, C., Muzio, M., Caiolfa, V., Kitamura, D., Restuccia, U., Bachi, A., Rocchi, M., Ponzoni, M., Ghia, P. & Caligaris-Cappio, F. (2010) HS1 has a central role in the trafficking and homing of leukemic B cells. Blood, 116, 3537-3546.
82. Screpanti, I., Bellavia, D., Campese, A.F., Frati, L. & Gulino, A. (2003) Notch, a unifying target in T-cell acute lymphoblastic leukemia? Trends in Molecular Medicine, 9, 30-35.
83. Scupoli, M.T. & Pizzolo, G. (2012) Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. Expert Reviews in Hematology, 5, 341-348.
84. Seke Etet, P.F., Vecchio, L. & Nwabo Kamdje, A.H. (2012) Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cellular Signalling, 24, 1433-1443.
85. Shachar, I. & Haran, M. (2011) The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leukemia & Lymphoma, 52, 1446-1454.
86. Sivina, M., Hartmann, E., Vasyutina, E., Boucas, J.M., Breuer, A., Keating, M.J., Wierda, W.G., Rosenwald, A., Herling, M. & Burger, J.A. (2012) Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia, 26, 1812-1820.
87. de Totero, D., Meazza, R., Zupo, S., Cutrona, G., Matis, S., Colombo, M., Balleari, E., Pierri, I., Fabbi, M., Capaia, M., Azzarone, B., Gobbi, M., Ferrarini, M. & Ferrini, S. (2006) Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood, 107, 3708-3715.
88. Trentin, L., Zambello, R., Agostini, C., Enthammer, C., Cerutti, A., Adami, F., Zamboni, S. & Semenzato, G. (1994) Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood, 84, 4249-4256.
89. Troeger, A., Johnson, A.J., Wood, J., Blum, W.G., Andritsos, L.A., Byrd, J.C. & Williams, D.A. (2012) RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood, 119, 4708-4718.
90. Tsukada, N., Burger, J.A., Zvaifler, N.J. & Kipps, T.J. (2002) Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood, 99, 1030-1037.
91. Virgilio, L., Narducci, M.G., Isobe, M., Billips, L.G., Cooper, M.D., Croce, C.M. & Russo, G. (1994) Identification of the TCL1 gene involved in T-cell malignancies. Proceedings of the National Academy of Sciences of the USA, 91, 12530-12534.
92. Vlad, A., Deglesne, P.A., Letestu, R., Saint-Georges, S., Chevallier, N., Baran-Marszak, F., Varin-Blank, N., Ajchenbaum-Cymbalista, F. & Ledoux, D. (2009) Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Research, 69, 6387-6395.
93. Watson, L., Wyld, P. & Catovsky, D. (2008) Disease burden of chronic lymphocytic leukaemia within the European Union. European Journal of Haematology, 81, 253-258.
94. Wickremasinghe, R.G., Prentice, A.G. & Steele, A.J. (2011) p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia, 25, 1400-1407.
95. Widhopf, G.F. 2nd, Rassenti, L.Z., Toy, T.L., Gribben, J.G., Wierda, W.G. & Kipps, T.J. (2004) Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood, 104, 2499-2504.
96. Wiernik, P.H. (2009) Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). Current Treatment Options in Oncology, 10, 1-15.
97. Wiestner, A. (2012) Emerging role of kinase targeted strategies in chronic lymphocytic leukemia. Blood, 120, 4684-4691.
98. Wiestner, A., Rosenwald, A., Barry, T.S., Wright, G., Davis, R.E., Henrickson, S.E., Zhao, H., Ibbotson, R.E., Orchard, J.A., Davis, Z., Stetler-Stevenson, M., Raffeld, M., Arthur, D.C., Marti, G.E., Wilson, W.H., Hamblin, T.J., Oscier, D.G. & Staudt, L.M. (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood, 101, 4944-4951.
99. Winer, E.S., Ingham, R.R. & Castillo, J.J. (2012) PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opinion on Investigational Drugs, 21, 355-361.
100. Woyach, J.A., Johnson, A.J. & Byrd, J.C. (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood, 120, 1175-1184.
101. Ysebaert, L. & Morschhauser, F. (2010) Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies. Expert Opinion on Investigational Drugs, 20, 1167-1174.
102. Zeng, Z., Samudio, I.J., Munsell, M., An, J., Huang, Z., Estey, E., Andreeff, M. & Konopleva, M. (2006) Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Molecular Cancer Therapeutics, 5, 3113-3121.
103. Zenz, T., Benner, A., Döhner, H. & Stilgenbauer, S. (2008) Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle, 15, 3810-3814.
104. Zhang, W., Trachootham, D., Liu, J., Chen, G., Pelicano, H., Garcia-Prieto, C., Lu, W., Burger, J.A., Croce, C.M., Plunkett, W., Keating, M.J. & Huang, P. (2012) Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nature Cell Biology, 14, 276-286.
105. Zucchetto, A., Sonego, P., Degan, M., Bomben, R., Dal Bo, M., Russo, S., Attadia, V., Rupolo, M., Buccisano, F., Steffan, A., Del Poeta, G., Pucillo, C., Colombatti, A., Campanini, R. & Gattei, V. (2005) Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): identification of markers with prognostic relevance. Journal of Immunological Methods, 305, 20-32.